Have you ever fallen, or nearly fallen asleep while driving? Have you been diagnosed with hypertension or diabetes? Do you suffer from depression or are you irritable much of the time? If you can answer yes to nay of these questions, you should ask your medical doctor to order a sleep study to determine is you are experiencing the effects of sleep apnea.
Dr. Avi Weisfogel specializes in treating sleep apnea from a dental standpoint and may refer patients to other dental practitioners who can fit them with oral appliances to properly treat the condition. He wants to improve the lives of his patients by helping them to achieve better sleep.
Partial air blockage is the typical cause for the most recognizable symptom for sleep apnea accompanied by loud snoring. The tongue may block the airway, or it might be the soft tissue at the back of the throat that relaxes during sleep. When air is blocked and breathing inhibited, the body’s natural reaction is to gasp for air which in turn wakes you up. You may go back to sleep, but the soft tissue relaxes again and the cycle continues.
Dr. Avi Weisfogel understands that even though there are some major signs that sleep apnea is present, the only way to fully diagnose this condition is with a thorough overnight sleep study. The study can be completed at a sleep center, or your doctor might order home monitoring to determine the severity of the condition and recommend the right treatment.
During sleep center studies sensors are applied to the scalp to show how and when subjects are asleep. Other sensors are placed close to the eyes to determine when, or if, patients achieve REM sleep. Other sensors are placed on the fingers to keep track of blood oxygen level and a patient’s breathing rate and heart rate are monitored, and the way air moves through the nose and mouth.
Dr. Avi Weisfogel is co-owner of Dental Sleep Masters of New Jersey and since 2010 has been involved with educating the public about how they can treat sleep apnea through treatment with oral appliances that do not interfere with normal, everyday life. He is proud of the work he is doing to improve patient’s lives.
Earlier this spring, Nobilis Health Corp.(NHC-TSX), a healthcare facility management and marketing firm, announced that it had closed a $25 million debt financing facility with GE Capital Healthcare Financial Services. The resulting capital would then be used to repay some of the company’s existing outstanding debt among other things. Their debt included a $12 million seller’s note from the acquisition of Athas Health by Nobilis in late 2014. The closure would also support Nobilis’ continued growth efforts and provide a new revolving line for working capital. Executing this plan helped Nobilis achieve one of its early 2015 goals of reducing their average borrowing costs while at the same time streamlining their capital structure. They were also excited about building a relationship with GE Capital, which they felt would provide another catalyst for growth throughout the rest of 2015 and into the future.
Nobilis’ specializes in is providing healthcare agencies with flexible capital programs to help customers expand their companies. They utilize innovative direct-to-patient marketing techniques which are focused on providing a limited set of procedures performed by local physicians at one of Nobilis’ many health care centers. They own and manage both ambulatory and acute care facilities as well as maintaining managing interests in ambulatory surgery centers in Dallas and Houston, Texas. In Houston, they also own an acute care hospital, which they purchased in September 2014 for $7.5 million in cash, as well as an urgent care clinic and two imaging centers. On September 23, 2015, Nobilis announced it had acquired a 60% stake and managing control of the former Freedom Pain Hospital in Scottsdale, Arizona, where they already own and maintain managing interests in other ambulatory surgery centers. They purchased the Freedom Pain Hospital for approximately $3.2 million.
Following this announcement, Nobilis’ stock dropped more than 22% in the third quarter of trading, but now is looking poised for a significant rebound. As of October 8, shares of Nobilis Health Corp. had risen by 4.02% in the previous five trading days and 8.17% during the previous 4 weeks. The company shares have rallied 375.21% from its 1 Year high price. The shares reached one year high at $9.34 on On Apr 20, 2015 and on Oct 24, 2014 it saw the one year low. The 50-Day Moving Average price is $5.13 and the 200 Day Moving Average price has been recorded as $6.23.
With worldwide markets down substantially heading into Q4 of 2015, Mackie Research Capital analyst Russell Stanley says Nobilis is his top pick, saying that he believes they will buck the current trend. Stanley says that Nobilis is a company with a strong track record of high organic growth and an even stronger track record when it comes to M&A. In a research update to clients, Stanley reiterated his “buy” rating on Nobilis and a one year target price of $12.50, which implies a return of 72% at the time of publication. After a brief period of strategic restructuring, Nobilis is poised to end 2015 with a strong finish and from there, the sky’s the limit.